Literature DB >> 15533206

Enfuvirtide: a new class of antiretroviral therapy for HIV infection.

J C Leao1, C Frezzini, S Porter.   

Abstract

Enfuvirtide is the first of a new class of antiretroviral agents recently approved for the treatment of human immunodeficiency virus (HIV)-1 infection. Present available data suggest that enfuvirtide may be a promising agent for the control of HIV infection in patients who have previously received reverse transcriptase inhibitor and protease inhibitor regimens and who are either intolerant to such drugs and/or who have gone into virological failure. Perhaps the greater limitation to the clinical use of enfuvirtide is the cost, limiting its use in the developing world.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533206     DOI: 10.1111/j.1601-0825.2004.01042.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  3 in total

1.  Relationship of long-term highly active antiretroviral therapy on salivary flow rate and CD4 Count among HIV-infected patients.

Authors:  J Vijay Kumar; P Venkat Baghirath; P Parameswar Naishadham; Sujai Suneetha; Lavanya Suneetha; P Sreedevi
Journal:  J Oral Maxillofac Pathol       Date:  2015 Jan-Apr

2.  Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.

Authors:  Ling Ni; Jieqing Zhu; Junjie Zhang; Meng Yan; George F Gao; Po Tien
Journal:  Biochem Biophys Res Commun       Date:  2005-04-29       Impact factor: 3.575

3.  Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.

Authors:  Ling Ni; George F Gao; Po Tien
Journal:  Biochem Biophys Res Commun       Date:  2005-07-08       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.